Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2010
11/25/2010WO2009132202A3 Macrocyclic compounds and their use as kinase inhibitors
11/25/2010WO2009121042A8 Quinazoline derivatives and methods of treatment
11/25/2010WO2009093250A3 Targeting of innate immune response to tumor site
11/25/2010US20100299767 Trem-2 gene and protein as inhibitors of expression of ga733-2, and transgenic animals comprising the same and uses thereof
11/25/2010US20100298444 Method for improving the therapeutic efficacy of curcuminoids and their analogs
11/25/2010US20100298437 Use of citrulline for treating undernutrition conditions
11/25/2010US20100298427 Anti-inflammatory compositions and their use
11/25/2010US20100298423 Nutraceutical composition from garcinia mangostana
11/25/2010US20100298421 Derivatives of taxol and closely related compounds
11/25/2010US20100298420 Compositions and Methods for Intracellular Delivery
11/25/2010US20100298415 Targeted schiff base complexes
11/25/2010US20100298412 Disulfide Chemotherapeutic Agents and Methods of Use Thereof
11/25/2010US20100298409 Compositions comprising stat3 sirna and methods of use thereof
11/25/2010US20100298408 Oligonucleotide Compositions with Enhanced Efficiency
11/25/2010US20100298406 Method of suppressing tumour growth
11/25/2010US20100298404 Translocation and mutant ROS kinase in human non-small cell lung carcinoma
11/25/2010US20100298403 MODIFIED POLY(PROPYLENE-IMINE) DENDRIMERS AND THEIR USE AS TRANSFECTION AGENTS FOR AMIONIC BIOACTIVE FACTORS ( as amended
11/25/2010US20100298402 Stilbene derivatives as pstat3/il-6 inhibitors
11/25/2010US20100298398 Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells
11/25/2010US20100298396 MANUFACTURE, COMPOSITIONS AND USES OF COAGULATION FACTOR VIIa MODULATOR
11/25/2010US20100298385 Protein kinase inhibitors useful for treatment of cancers
11/25/2010US20100298383 Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms)
11/25/2010US20100298377 Novel substituted indazoles, the preparation thereof and use of same in therapeutics
11/25/2010US20100298374 Nitrile derivatives and their pharmaceutical use and compositions
11/25/2010US20100298370 Benzothiazolyl thienopyridine derivatives and uses thereof
11/25/2010US20100298369 Berbamine derivatives
11/25/2010US20100298368 Antagonists of pgd2 receptors
11/25/2010US20100298367 Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders
11/25/2010US20100298364 salts 756
11/25/2010US20100298363 Use of carboxyamidotriazole (CAI) orotate in macular degeneration
11/25/2010US20100298361 Alkylthio Pyrimidines As CRTH2 Antagonists
11/25/2010US20100298358 Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors
11/25/2010US20100298357 Maleate salts of a quinazoline derivative useful as an antiangiogenic agent
11/25/2010US20100298355 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
11/25/2010US20100298352 Small molecule inhibitors of cancer stem cells
11/25/2010US20100298351 Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti-cancer agents
11/25/2010US20100298349 Thienopyrimidine compounds and compositions
11/25/2010US20100298348 Method of Decreasing Ubiquitylated Protein Levels
11/25/2010US20100298344 Polycationic Compounds And Uses Thereof
11/25/2010US20100298339 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use
11/25/2010US20100298338 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit
11/25/2010US20100298337 Organic Compounds
11/25/2010US20100298334 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
11/25/2010US20100298331 Triazinone and diazinone derivatives useful as hsp90 inhibitors
11/25/2010US20100298329 Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers
11/25/2010US20100298326 Carboxamide compounds and their use as calpain inhibitors
11/25/2010US20100298325 Pyridine derivatives for the treatment of amyloid-related diseases
11/25/2010US20100298323 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
11/25/2010US20100298322 Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
11/25/2010US20100298321 Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
11/25/2010US20100298320 Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use
11/25/2010US20100298319 Pyrimidine substituted purine derivatives
11/25/2010US20100298316 Benzothiazoles Having Histamine H3 Receptor Activity
11/25/2010US20100298315 Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmnaceutical compositions and novel use as met inhibitors
11/25/2010US20100298313 Method of using imidazolothiazole compounds for the treatment of disease
11/25/2010US20100298312 Substituted pyrimidinyl-amines as protein kinase inhibitors
11/25/2010US20100298308 Compositions and methods for bone formation and remodeling
11/25/2010US20100298306 (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease
11/25/2010US20100298302 Novel protein kinase modulators
11/25/2010US20100298301 Oxazole tyrosine kinase inhibitors
11/25/2010US20100298298 Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof
11/25/2010US20100298297 Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof
11/25/2010US20100298295 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
11/25/2010US20100298290 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
11/25/2010US20100298286 Organic Compounds
11/25/2010US20100298285 Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
11/25/2010US20100298281 Steroid-Derived Cyclopamine Analogs and Methods for Using the Same in the Prevention or Treatment of Cancer
11/25/2010US20100298272 Phosphorus containing heterocyclic compounds, sugar analogues, and compositions having anti-cancer activity containing the same
11/25/2010US20100298271 Compounds for use in the treatment of cancer
11/25/2010US20100298270 Novel Compounds and Methods of Using Them
11/25/2010US20100298263 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
11/25/2010US20100298260 Non-anticoagulant polysaccharide compositions
11/25/2010US20100298255 Methods for providing personalized medicine test ex vivo for hematological neoplasms
11/25/2010US20100298250 Compositions and methods for extracting and using phytochemicals for the treatment of influenza
11/25/2010US20100298248 Biologically active macrolides, compositions, and uses thereof
11/25/2010US20100298246 Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same
11/25/2010US20100298236 Soluble gp130 muteins with improved binding activity
11/25/2010US20100298234 Cancer therapeutic agents comprising a ligand for the neuromedin u receptor 2 (fm4) molecule as an active ingredient
11/25/2010US20100298233 Compositions and methods related to profiling a plurality of cells based on peptide binding
11/25/2010US20100298232 Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof
11/25/2010US20100298225 Peptide gap junction modulators
11/25/2010US20100298222 Use of an agent that restores tissue perfusion and oxygenation
11/25/2010US20100298219 Method of treating cancer, neoplastic disorders, and symptoms thereof with compounds
11/25/2010US20100298218 Single Branch Heparin-Binding Growth Factor Analogs
11/25/2010US20100298217 Csf-1r mutants
11/25/2010US20100298203 Sdf-i-based glycosaminoglycan antagonists and methods of using same
11/25/2010US20100298201 Peptidomimetic macrocycles with improved properties
11/25/2010US20100298200 Compounds and assays for controlling Wnt activity
11/25/2010US20100298164 Structure-based approach to design of inhibitors of protein-processivity factor interactions
11/25/2010US20100297732 Vectors with modified protease-dependent tropism
11/25/2010US20100297695 Nucleic Acids Encoding Chimeric CD154 Polypeptides
11/25/2010US20100297665 Method for testing and screening p38 map kinase modifiers
11/25/2010US20100297650 Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
11/25/2010US20100297262 Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
11/25/2010US20100297255 Malleable implants containing demineralized bone matrix
11/25/2010US20100297245 Methods and compositions for oral administration of protein and peptide therapeutic agents
11/25/2010US20100297244 Nanodispersion
11/25/2010US20100297242 Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
11/25/2010US20100297240 1- [2- (2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
11/25/2010US20100297230 Compositions and methods for prostate and menstrual/menopausal related health
1 ... 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 ... 2211